On May 20, 2020 OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, reported that data highlighting the ongoing clinical studies targeting Globo H and AKR1C3 antigen in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program from May 29–31, 2020 (Press release, OBI Pharma, MAY 20, 2020, View Source [SID1234558351]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These studies will be presented by the lead investigators of OBI Pharma’s first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).

"Based upon our anti-Globo H and AKR1C3 targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have posters on the progress of our trials presented at ASCO (Free ASCO Whitepaper)20 for our first-in-class therapeutics Adagloxad Simolenin, OBI-999, and OBI-3424. We look forward to providing future updates of our studies, which we believe could offer potential therapeutic benefits to patients suffering from cancer," stated Tillman Pearce, MD, Chief Medical Officer at OBI Pharma.

Abstract: TPS599 / Poster: 91
Title: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Session Title: Breast Cancer—Local/Regional/Adjuvant
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time
View Source

Abstract: TPS3657 / Poster: 387
Title: A phase I/II, open‑label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI‑999 in patients with advanced solid tumors.
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time
View Source

Abstract: TPS3658 / Poster: 388
Title: A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC).
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time
View Source

The above poster presentations will be available online at www.obipharma.com on May 29, 2020.